News Chart Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
17.2 ^HKD	+1.42%		+2.99%	+23.74%

May. 06	Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy	MT
May. 06	Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration	CI

43ed6991aa5dc3ee5.kLSjLLhG-_ar6QJtfq5PE1LdZzJv8GZmeicdNyGd9Kg.wP_kdtESg7_RnjI3LpkhQzOxSgoCwVYRAnd7QlL5wpj5845H9zOthJ-McQ~adf02ca8839249cfd404954f2351a4f1